Evidence map›Paper›PMID 41746257›Full record

ArticleBlood2026

Differential role of CREBBP missense and truncating mutations in germinal center development and lymphomagenesis.

Chuanjiang Yu, Mara Holloman, Andrew Kim, Yunchao Chang, Stefanie N Meyer, Antony B Holmes, Bowen Cai, Tongwei Mo, Katia Basso, Kostiantyn Dreval and 5 more

Abstract read
In one paragraph

Article in Blood, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Missense Mutations in the KAT Domain ofInternational journal of molecular sciences · 2025
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Chuanjiang YuInstitute for Cancer Genetics, Columbia University, New York, NY.ORCID 0009-0007-4616-6128
Mara HollomanInstitute for Cancer Genetics, Columbia University, New York, NY.
Andrew KimInstitute for Cancer Genetics, Columbia University, New York, NY.
Yunchao ChangDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, TN.ORCID 0009-0005-3906-5543
Stefanie N MeyerInstitute for Cancer Genetics, Columbia University, New York, NY.
Antony B HolmesInstitute for Cancer Genetics, Columbia University, New York, NY.ORCID 0000-0001-7559-2678
Bowen CaiInstitute for Cancer Genetics, Columbia University, New York, NY.
Tongwei MoInstitute for Cancer Genetics, Columbia University, New York, NY.
Katia BassoInstitute for Cancer Genetics, Columbia University, New York, NY.ORCID 0000-0002-9316-6039
Kostiantyn DrevalCentre for Lymphoid Cancer, BC Cancer Research Institute, Vancouver, BC, Canada.
Ryan D MorinCentre for Lymphoid Cancer, BC Cancer Research Institute, Vancouver, BC, Canada.ORCID 0000-0003-2932-7800
Govind BhagatDepartment of Pathology and Cell Biology, Columbia University, New York, NY.ORCID 0000-0001-6250-048X
Charles G MullighanDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, TN.ORCID 0000-0002-1871-1850
Riccardo Dalla-FaveraInstitute for Cancer Genetics, Columbia University, New York, NY.
Laura PasqualucciInstitute for Cancer Genetics, Columbia University, New York, NY.ORCID 0000-0001-6819-7370

Funding

From pathogenesis to new therapeutic targets in Diffuse Large B cell LymphomaR35CA210105 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Riccardo Dalla-Favera · 2016 to 2026
$10.0M
Role of CREBBP missense mutations in lymphomagenesisR01CA260176 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Riccardo Dalla-Favera · 2022 to 2026
$2.3M
National Cancer Institute (NCI), National Institutes of Health (NIH)National Cancer Institute (NCI), National Institutes of Health (NIH) P30-CA013696National Cancer Institute (NCI), National Institutes of Health (NIH) R01-CA161202National Cancer Institute (NCI), National Institutes of Health (NIH) R01-CA207963National Cancer Institute (NCI), National Institutes of Health (NIH) R35-CA197695NCI NIH HHS P30-CA021765NCI NIH HHS R01 CA260176NCI NIH HHS R35 CA210105
6 · The paper itself

Abstract

abstractTruncating and missense mutations of the CREBBP gene are highly prevalent in follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL), the most common lymphoid malignancies. These mutations are acquired early during tumor evolution by a common precursor cell (CPC) and lead to either complete protein loss or single amino acid substitutions in the lysine acetyltransferase (KAT) domain. As a result, CREBBP is impaired in its ability to acetylate enhancer histones and nonhistone proteins implicated in the germinal center (GC) reaction, the structure from which these tumors originate. However, whether truncating and KAT domain missense mutations are functionally equivalent in instructing the CPC remains unexplored. Using a conditional GC-specific knockin mouse model for the highly frequent CREBBP-R1446H amino acid change (CrebbpRH), we show that, compared with complete Crebbp loss, missense mutants impose distinct quantitative and qualitative effects on the GC response. CrebbpRH controls unique transcriptional programs leading to the preneoplastic expansion of GCs with abnormal architecture, increased percentage of T follicular helper cells, and a skewed immune response toward memory B-cell differentiation. The expression of CrebbpRH, but not Crebbp loss, was by itself sufficient to initiate malignant transformation, indicating a stronger tumor-promoting activity. Notably, lymphoma cells with CREBBPRH and CREBBP loss showed distinct sensitivity to CREBBP/p300 small-molecule inhibitors. Together with the differential distribution of missense and truncating mutations in FL and DLBCL, these findings have implications for the pathogenesis and therapeutic targeting of these cancers.

Indexed as

CREB-Binding ProteinGerminal CenterLymphomaLymphoma, FollicularMutation, MissenseAnimalsCarcinogenesisCell Transformation, NeoplasticGene Expression Regulation, NeoplasticHumansMiceCREB-Binding ProteinCrebbp protein, mouse

Identifiers

PMID41746257
PMCPMC13277655

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.